S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker

Illumina - ILMN Stock Forecast, Price & News

$220.00
+3.05 (+1.41%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$214.24
$220.44
50-Day Range
$194.01
$228.15
52-Week Range
$173.45
$371.16
Volume
754,647 shs
Average Volume
1.47 million shs
Market Capitalization
$34.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$249.40

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
13.4% Upside
$249.40 Price Target
Short Interest
Healthy
2.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.01mentions of Illumina in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$2.26 M Sold Last Quarter
Proj. Earnings Growth
153.19%
From $1.41 to $3.57 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

176th out of 1,005 stocks

Analytical Instruments Industry

7th out of 28 stocks


ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

Illumina responds to latest salvo from Carl Icahn
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Illumina Should Heed Carl Icahn, Give Up on Grail
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
2/07/2023
Today
3/26/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
10,260
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$249.40
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$150.00
Forecasted Upside/Downside
+13.4%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
16 Analysts

Profitability

Net Income
$-4,404,000,000.00
Pretax Margin
-94.59%

Debt

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$4.70 per share
Book Value
$41.95 per share

Miscellaneous

Free Float
157,795,000
Market Cap
$34.76 billion
Optionable
Optionable
Beta
1.15

Social Links


Key Executives

  • Francis A. deSouzaFrancis A. deSouza
    President, Chief Executive Officer & Director
  • Kevin Pegels
    Chief-Global Operations
  • Joydeep Goswami
    CFO, Chief Strategy & Development Officer
  • Phillip G. FebboPhillip G. Febbo
    Chief Medical Officer
  • Alex Aravanis
    CTO, Head-Research & Product Development













ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price forecast for 2023?

16 equities research analysts have issued 1 year price objectives for Illumina's shares. Their ILMN share price forecasts range from $150.00 to $350.00. On average, they predict the company's stock price to reach $249.40 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2023?

Illumina's stock was trading at $202.20 on January 1st, 2023. Since then, ILMN stock has increased by 8.8% and is now trading at $220.00.
View the best growth stocks for 2023 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings results on Tuesday, February, 7th. The life sciences company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.25 by $0.11. The life sciences company earned $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a negative net margin of 96.12% and a positive trailing twelve-month return on equity of 3.79%. Illumina's revenue was down 9.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 EPS.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY23 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of $1.25-1.50 for the period, compared to the consensus earnings per share estimate of $1.38. The company issued revenue guidance of +7-10% yr/yr to $4.9-5.04 billion, compared to the consensus revenue estimate of $4.97 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.60%), Edgewood Management LLC (4.12%), Polen Capital Management LLC (3.21%), Alliancebernstein L.P. (2.46%), Geode Capital Management LLC (1.83%) and Price T Rowe Associates Inc. MD (1.34%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $220.00.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $34.76 billion and generates $4.58 billion in revenue each year. The life sciences company earns $-4,404,000,000.00 in net income (profit) each year or ($28.00) on an earnings per share basis.

How many employees does Illumina have?

The company employs 10,260 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 3/26/2023 by MarketBeat.com Staff